• Home
  • Sustainable Investment Week
    • ESG
    • Sustainable Investment
    • Sustainable Investing
  • Equities
    • UK
    • Global
    • Europe
    • US
    • Asia
    • Emerging markets
    • Specialist
  • Bonds
  • Multi-asset
  • Funds
    • Unit trusts/OEICs
    • Investment Trusts
    • VCTs/EIS
    • Platforms
    • ETFs
    • Pensions
  • Regulation
  • Diversity
  • People moves
  • Events
  • Financial library
  • Industry blogs
  • Digital Edition
  • Newsletters
  • Sign in
    • logged-in-corporate-menuYou are currently accessing Investment Week via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0) 1858 438800

      Email: [email protected]

      • Sign in
     
      • Account details
      • Newsletters
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
    • Newsletters
    • Facebook
    • YouTube
    • Instagram
  • Register
  • Events
    • Upcoming events
      event logo
      UK Equities Market Briefing

      Industry commentators have forecast a turnaround in fortunes for the unloved UK market in 2021 as vaccines are rolled out and the country starts to recover from the Covid-19 pandemic, while the threat of a no-deal Brexit has now been removed. During this event, fund managers running portfolios investing across the market-cap spectrum will give their views on potential tailwinds for the UK market and identify where they are finding the most compelling value opportunities in a post-Brexit world.

      • Date: 23 Feb 2021
      • ONLINE, ONLINE
      event logo
      Fund Selector Briefing: Scotland 2021

      Investment Week's Fund Selector Briefing: Scotland 2021 is taking place live online on 25th February from 09:00 - 12:35. Aimed at senior investment professionals involved in the fund selection process, this event will provide the opportunity to hear from, and question, fund managers and networking with your peers.

      • Date: 25 Feb 2021
      • ONLINE, ONLINE
      event logo
      European equities: How to stay in sync with the cycle and prepare for recovery

      Our expert panellists on Investment Week’s latest webinar will discuss how investors in Europe should best position themselves for the new economic cycle, which is likely to have very different characteristics from the last.

      • Date: 04 Mar 2021
      • ONLINE, ONLINE
      event logo
      Fund Selector Briefing: Channel Islands 2021

      This interactive briefing will bring together senior investment professionals involved in the fund selection process from across the Channel Islands to hear from and question leading fund managers covering a range of asset classes.

      • Date: 04 Mar 2021
      • ONLINE, ONLINE
      View all events
      Follow our events

      Sign up to receive email alerts about our events

      Sign up

  • White papers
    • Fidelity logo whitebackground1200 630px 1 120x194
      The ETF Evolution

      In this exclusive magazine exploring the evolution of quality and income ETF strategies, King reveals that each ETF follows an investment strategy developed by the group's in-house research team that leverages fundamental active insights to inform the factor definitions and applies portfolio construction principles to mitigate the unintended biases.

      Download
      7ded04ac5957a69da8d1df41c8f21a0c33988d8f 1 120x194
      A bet on the UK bounce back

      David Cumming, Aviva Investors' chief investment officer for equities, last year witnessed turbulent times for UK equities but he remains positive about the market in which he has a personal as well as a professional stake.

      Download
      Find white papers
      Search by title or subject area
      View all white papers
  • Industry blogs
  • Digital Edition
Investment Week
Investment Week
Sponsored by BMO
  • Home
  • Sustainable Investment Week
  • Equities
  • Bonds
  • Multi-asset
  • Funds
  • Regulation
  • Diversity
  • People moves
  • logged-in-corporate-menuYou are currently accessing Investment Week via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0) 1858 438800

    Email: [email protected]

    • Sign in
 
    • Account details
    • Newsletters
    • Contact support
    • Sign out
 
  • Trending
  • IW 22 Feb issue
  • Past IW issues
  • Phoenix SLA deal
  • Gender lens funds
  • ESG Festival
  • Industry Voice

Industry Voice - strong sector fundamentals despite political uncertainties

Biotech investments

  • Investment Week
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Share on Whatsapp
  • Send to  
0 Comments

2016 was a challenging year for biotechnology investors but the sector will continue to demonstrate its strength as a source of innovation, says Daniel Koller, Head of the Investment Team at BB Biotech

Market volatility and evolving political pressure in the US made 2016 a testing year for the biotech sector. In the week following the election of President Donald Trump in November, the Nasdaq Biotech Index jumped 10%. However, a little over a month later the year closed with large-cap biotechnology companies trading close to an all-time price-to-earnings multiple low.

Alongside the pullbacks and rallies of market sentiment, 2016 also saw a slowdown in large-scale M&A activity. Despite all this sector fundamentals are remaining strong and we have seen positive results across the biotechnology industries.

This is why we see a likelihood for accelerated M&A consolidation this year. The recently announced acquisition of Ariad Pharma by Takeda and the Actelion takeover by Johnson & Johnson mark just the beginning of this trend.

With this confidence in mind, we have maintained a 5% dividend yield on the trust as we feel positive about the sector's prospects in 2017.

BB Biotech's performance

With a total return of 0.3% in CHF terms and 1.9% in euro terms, BB Biotech has already weathered the storm of a challenging 2016 for biotechnology investors, with the trust's share price performance substantially influenced by the discount resolution.

In the fourth quarter of 2016, we increased our positions in companies including Alexion and Novo Nordisk as well as in smaller-cap companies such as Intra-Cellular, Macrogenics, Juno and Agios. Performance in this quarter was buffeted by initial positive moves following the US presidential election before the focus turned back to the topic of healthcare costs and drug price inflation.

The portfolio closed the year at -19.1% in CHF, at -17.6% in euro terms and -20.6% in US dollar terms, slightly ahead of the Nasdaq Biotech Index.

Exciting 2017 as storms subside

2017 will bring an acceleration of important product approvals for the industry. The launch of Spinraza for SMA patients, Niraparib for ovarian cancer patients, and targeted cell-based cancer therapies are key examples in BB Biotech's portfolio.

With biotechnology valuations at very attractive levels, more acquisitions by large players, including pharmaceutical firms, are expected. The actions of the incoming presidential administration in the US may accelerate this likely trend - and we expect investors to follow suit. The repeal and reworking of the Affordable Care Act (ACA) will be front and centre throughout the year, and there may be choppy reactions to possible drug price controls or moderation in the US.

Despite these transitional events, which we will monitor closely, we remain strongly convinced that the future of the biotechnology industry is bright. The sector will further demonstrate its strength as a source of innovation - and notwithstanding short-term uncertainties from political changes, we believe these sources will be converted into substantial value for patients, care providers, the healthcare system at large and, of course, investors which includes BB Biotech shareholders.

We look forward to an exciting 2017 and remain dedicated to finding, analysing and investing in leading-edge biotechnology firms with exciting news flow and robust growth prospects. We will propose a regular dividend of CHF 2.75 per share at the general assembly on 16 March 2017 which is consistent with the 5% dividend yield applied to the average share price in December 2016.

Dr. Daniel Koller joined the Swiss investment trust BB Biotech AG in 2004 as senior portfolio manager specialised in biotechnology. Since 2010 he has been head of the investment team. Before joining the company he spent four years in the financial sector, initially as an equity analyst at UBS Warburg and then as a private equity investor at equity4life. Dr. Koller studied biochemistry at the Swiss Federal Institute of Technology and earned a doctorate in biotechnology while working at Cytos Biotechnology

For more information, please contact:
Claude Mikkelsen
[email protected], +44 203 770 67 85  , www.bbbiotech.com

Disclaimer

All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Share on Whatsapp
  • Send to  
  • Topics
  • Industry Voice
  • Industry Voice
  • BB Biotech
  • large cap
blog comments powered by Disqus
Back to Top
Trustpilot

 

  • Contact us
  • Marketing solutions
  • About Incisive Media
  • Terms and conditions
  • Policies
  • Careers
  • Twitter
  • LinkedIn
  • Newsletters
  • Facebook
  • YouTube
  • Instagram

© Incisive Business Media (IP) Limited, Published by Incisive Business Media Limited, New London House, 172 Drury Lane, London WC2B 5QR, registered in England and Wales with company registration numbers 09177174 & 09178013

Digital publisher of the year
Digital publisher of the year 2010, 2013, 2016 & 2017
Loading